Crossmark

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

Crossref DOI link: https://doi.org/10.1038/s41467-019-12409-w

Published Online: 2019-11-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sale, Matthew J.

Minihane, Emma

Monks, Noel R.

Gilley, Rebecca

Richards, Frances M. https://orcid.org/0000-0001-7947-7853
Schifferli, Kevin P.

Andersen, Courtney L. https://orcid.org/0000-0003-2064-2273
Davies, Emma J.

Vicente, Mario Aladren

Ozono, Eiko

Markovets, Aleksandra

Dry, Jonathan R.

Drew, Lisa

Flemington, Vikki

Proia, Theresa

Jodrell, Duncan I. https://orcid.org/0000-0001-9360-1670
Smith, Paul D. https://orcid.org/0000-0002-2812-5978
Cook, Simon J. https://orcid.org/0000-0001-9087-1616
Funding

Funding for this research was provided by:

Cancer Research UK (A14867)

RCUK | Biotechnology and Biological Sciences Research Council (BB/J004456/1, BB/P013384/1, BBS/E/B000C0433, BBS/E/B/000C0434)

AstraZeneca
License Information

Text and Data Mining valid from 2019-11-14

Version of Record valid from 2019-11-14
More Information

Article History

Received: 18 December 2018

Accepted: 6 September 2019

First Online: 14 November 2019

Competing interests

: N.R.M., K.P.S., C.L.A., E.J.D., A.M., J.R.D., L.D., V.F., T.P. and P.D.S. are paid employees and shareholders of AstraZeneca. D.I.J. received laboratory and clinical trial funding from AstraZeneca. Some work in S.J.C.’s laboratory, including salary for M.J.S., was supported by a sponsored research collaboration funded by AstraZeneca; however, S.J.C. receives no personal payment of any kind from AstraZeneca. M.J.S. was also a direct employee of AstraZeneca for 1 year. All other authors declare no competing interests.

Document is current

Any future updates will be listed below